All News
Filter News
Found 180 articles
-
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
3/23/2023
BridgeBio Pharma, Inc. today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in its Phase 1/2 clinical trial of BBP-398, an investigational SHP2 inhibitor, with Bristol Myers Squibb’s OPDIVO® (nivolumab) in advanced solid tumors with KRAS mutations (NCT05375084)
-
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
3/14/2023
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.
-
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
2/27/2023
Revolution Medicines, Inc. announced its financial results for the quarter and year ended December 31, 2022, and provided an update on corporate progress.
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
2/23/2023
BridgeBio Pharma, Inc. today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company’s operations.
-
Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules
2/14/2023
Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, today announced that it has raised a $77.3 million Series B financing and made key appointments to its leadership team. Existing investors, including The Column Group, Two Sigma Ventures, 8VC, and Nextech, participated in the Series B round, joined by additional new investors, including Canada Pension Plan Investment Board (CPP Investments).
-
KRAS Inhibitor Drug LUMAKRAS Sotorasib Krazati Adagrasib Market Forecast 2029
2/3/2023
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:
-
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
2/2/2023
Verastem Oncology today outlined key strategic priorities and upcoming catalysts to support its lead compound RAF/MEK clamp avutometinib in RAS pathway-driven cancers.
-
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
1/31/2023
Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.
-
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
1/24/2023
Verastem Oncology (Nasdaq: VSTM) today announces positive interim data from Part A of the ongoing RAMP 201 (ENGOTov60/GOG3052) international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).
-
In a presentation led by Robert J. Bradway, Amgen chairman and chief executive officer, the company covered recent acquisitions, Repatha and Lumakras updates, biosimilars and its broader financial outlook.
-
In a recently published study, MD Anderson researchers achieved curative responses in pancreatic cancer models by targeting checkpoints in T cells and myeloid suppressor cells.
-
Verastem Oncology Appoints Rob Gagnon to Board of Directors
12/15/2022
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022.
-
Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.
-
Mirati's KRAS Inhibitor Demonstrates Encouraging Clinical Profile in Latest Data Drop (Updated)
12/6/2022
Mirati's adagrasib demonstrated a solid safety profile in new data released Monday. Despite this, the company's stock fell 8% in after-hours trading. -
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
11/7/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate progress.
-
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/3/2022
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.
-
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
11/3/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s operations.
-
AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
11/3/2022
Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022.
-
Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
-
Verastem Oncology Appoints Anil Kapur to Board of Directors
10/20/2022
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.